Paul Hastings Advises Deerfield Funds on Acquisition of Actio Biosciences by Jazz Pharmaceuticals

Paul Hastings LLP advised funds managed by Deerfield Management Company L.P., in their capacity as significant stockholders of Actio Biosciences, on Actio’s pending acquisition by Jazz Pharmaceuticals for $820 million upfront and up to $500 million in contingent consideration. The firm is also advising the Deerfield funds on the contemplated spinout and financing of certain Actio programs relating to genetic rare neurological diseases.   

Corporate partners Samuel A. Waxman and Andrew Goodman and of counsel Adam Winer led the Paul Hastings team, which also included Tax partner Andrew Davis and associate Michael Pelle and Private Equity & Corporate Finance partner Tracey Chenoweth and of counsel Erik Zakarin.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit www.paulhastings.com.